Evidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy

Pediatric Rehabilitation

Volumn 6, Issue 2, 2003, Pages 85-96

  Wong, Virginia ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Botox (Allergan); Botulinum Toxin Type A (BTX); Cerebral Palsy (CP); Children; Drooling; Dysport (Ipsen); Muscle Spasticity; Randomized Controlled Trials (RCT)

Indexed keywords

EID: 85013607898     PISSN: 13638491     EISSN: 14645270     Source Type: Journal    
DOI: 10.1080/1363849031000139306     Document Type: Article

References (77)

1. BRIN, M. F.: Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl, 6: S146-S168, 1997.
2. JANKOVIC, J. and BRIN, M. P.: Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl, 6: S129-S145, 1997.
3. SIMPSON, D. M.: Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve Suppl, 6: Sl69-Sl75, 1997.
4. COSGROVE, A. P. and GRAHAM, H. K.: Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Developments in Medicine and Child Neurology, 36: 379385, 1994.
5. FORRSBERG, H. and TEDROFF. K. B.: Botulinum toxin treatment in cerebral palsy: intervention with poor evaluation? Developments in Medicine and Child Neurology, 39: 635-640,1997.
6. COCHRANE, W.: The combination of estimates from different experiments. Biometrics, 10: 101-129, 1954.
7. CLARKE, M. H.: Cochrane Reviewers' Handbook 4.1. [www.cochrane.de/cochrane/hbook.htm] (Oxford, UK: The Cochrane Collaboration), 2000.
8. SACKETT, D., STRAUS, S. E., RICHARDSON, W. S. et al.: Evidencebased Medicine, 2nd edn (Churchill Livingstone), 2000.
9. RUSSMAN, B. S., TILTON, A. and GORMLEY JR., M. E.: Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl, 6: S181-S193, 1997.
10. CARR, L. J., COSGROVE, A. P., GRINGRAS, P. et al.: Position paper on the use of botulinum toxin in cerebral palsy. UK Botulinum toxin and Cerebral Palsy Working Party. Archives of Diseases in Children, 79: 271-273, 1998.
11. GRAHAM, H. K., AOKI, K. R., AUTTI-RAMO, I. et al.: Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait and Posture, 11: 67-79, 2000.
12. GRAHAM, H.: Botulinum toxin A in cerebral palsy: functional outcomes. Journal of Paediatrics, 137: 300-303, 2000.
13. ADE-HALL, R. A. and MOORE, A. P.: Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database System Review, 2: CD001408, 2000.
14. PETERSEN, M. C. and PALMER, F. B.: Advances in prevention and treatment of cerebral palsy. Mental Retardation Developments and Disability Research Review, T. 30-37, 2001.
15. KIRSCHNER, J., BERWECK, S., MALL, V. et al.: Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option. Journal of Neurology, 24» (suppl 1): 28-30, 2001.
16. EDGAR, T. S.: Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review. Journal of Child Neurology, 16: 37-46, 2001.
17. HOULTRAM, J., NOBLE, I., BOYD, R. N. et al.: Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. European Journal of Neurology, 8 (suppl 5): 194-202, 2001.
18. BOYD, R. N. and HAYS, R. M.: Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. European Journal of Neurology, 8 (suppl 5): 1-20, 2001.
19. BOYD, R. N. and HAYS, R. M.: Outcome measurement of effectiveness of botulinum toxin type A in children with cerebral palsy: an ICIDH-2 approach. European Journal of Neurology, 8 (suppl 5): 167-177, 2001.
20. WASIAK, J., WALLEN, M., VILLANUEVA, E. et al.: Botulinum toxin type A in the treatment of upper limb plasticity in children with cerebral palsy (protocol in the Cochrane Database of Systematic Reviews, [www.cochranelibrary.com/enter/]). The Cochrane Library, 1:, 2001.
21. KOMAN, L. A., MOONEY, J. F. 3rd, SMITH, B. et al.: Management of cerebral palsy with botulinum-A toxin: preliminary investigation. Journal of Pediatric Orthopedics, 13: 489-495, 1993.
22. CORRY, I. S., COSGROVE, A. P., DUFFY, C. M. et al.: Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomized prospective trial. Journal of Paediatric Orthopaedics, 18: 304-311, 1998.
23. WISSEL, J., HEIMEN, F., SCHENKEL, A. et al.: Botulinum toxin A in thé management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of 'high-dose' versus 'low-dose' treatment. Neuropediatrics, 30: 120124, 1999.
24. SUTHERLAND, D. H., KAUFMAN, K. R., WYATT, M. P. et al.: Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture, 10: 1-9, 1999.
25. UBHI, T., BHAKTA, B. B., IVES, H. L. et al.: Randomized doubleblind placebo-controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Archives of Diseases in Children, 83: 481-487, 2000.
26. KOMAN, L. A., MOONEY, J. F. 3rd, SMITH, B. P. et al.: Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. Journal of Pediatrie Orthopedics, 20: 108-115, 2000.
27. BOYD, R. N., DOBSON, F., PARROTT, J. et al.: The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. European Journal of Neurology, 8 (suppl 5): 109-119, 2001.
28. LOVE, S. C., VALENTINE, J. P., BLAIR, E. M. et al.: The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial. European Journal of Neurology, 8 (suppl 5): 50-58, 2001.
29. REDDIHOUGH, D. S., KING, J. A., FOSANG, A. et al.: Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Developments in Medicine and Child Neurology, 44: 820-827, 2002.
30. POLAK, F., MORTON, R., WARD, C. et al.: Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegie cerebral palsy. Developments in Medicine and Child Neurology, 44: 551-555, 2002.
31. BAKER, R., JASINSKI, M., MACIAG-TYMECKA, I. et al.: Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Developments in Medicine and Child Neurology, 44: 666-675,2002.
32. CALDERON-GONZALEZ, R., CALDERON-SEPULVEDA, R., RINCONREYES, M. et al.: Botulinum toxin A in management of cerebral palsy. Pediatrie Neurology, 10: 284-288, 1994.
33. DENISLIC, M. and MEH, D.: Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics, 26: 249-252, 1995.
34. MEINEN, F., WISSEL, J., PHILIPSEN, A. et al.: International neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics, 28: 307313, 1997.
35. ARENS, L. J., LEARY, P. M. and GOLDSCHMIDT, R. B.: Experience with botulinum toxin in the treatment of cerebral palsy. South African Medical Joumal, 87: 1001-1003, 1997.
36. MALL, V., HEINEN, F., LINDER, M. et al.: Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatrie Rehabilitation, 1:235-237, 1997.
37. ZELNIK, N., GILADI, N., GOIKHMAN, I. et al.: The role of botulinum toxin in the treatment of lower limb spasticity in children with cerebral palsy--a pilot study. Israeli Journal of Medical Science, 33: 129-133, 1997.
38. WONG, V.: Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatric Neurology, 18: 124-131, 1998.
39. EAMES, N. W., BAKER, R., HILL, N. et al.: The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Developments in Medicine and Child Neurology, 41: 226-232, 1999.
40. ROCCELLA, M.: The type A botulinum toxin in the treatment of spasticity in evolutive age. Minerva Pediatrics, 51: 367-373, 1999.
41. CORRY, I. S., COSGROVE, A. P., DUFFY, C. M. et al.: Botulinum toxin A in hamstring spasticity. Gait Posture, 10: 206-210, 1999.
42. FLETT, P. J., STERN, L. M., WADDY, H. et al.: Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. Journal of Paediatric Child Health, 35: 71-77, 1999.
43. BOYD, R. N., PLIATSIOS, V., STARR, R. et al.: Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Developments in Medicine and Child Neurology, 42: 32-41, 2000.
44. FRIEDMAN, A., DIAMOND, M., JOHNSTON, M. V. et al.: Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. American Journal of Physical Medicine Rehabilitation, 79: 53-59; quiz 75-76, 2000.
45. SUPUTTITADA, A.: Managing spasticity in pédiatrie cerebral palsy using a very low dose of botulinum toxin type A: preliminary report. American Journal of Physical Medicine Rehabilitation, 79: 320-326, 2000.
46. GARCIA RUIZ, P. J., PASCUAL PASCUAL, I. and SANCHEZ BERNARDOS, V.: Progressive response to botulinum A toxin in cerebral palsy. European Journal of Neurology, 7: 191-193, 2000.
47. UBHI, T.: Treatment of paediatric cerebral palsy with Dysport. Hospital Medicine, 61: 718-721, 2000.
48. JACOBS, J. M.: Management options for the child with spastic cerebral palsy. Orthopedic Nursing, 20: 53-59; quiz 59-61, 2001.
49. BJORNSON, K. F. and MCLAUGHLIN, J. F.: The measurement of health-related quality of life (HRQL) in children with cerebral palsy. European Journal of Neurology, 8 (suppl 5): 183-193, 2001.
50. CHAMBERS, H. G.: Treatment of functional limitations at the knee in ambulatory children with cerebral palsy. European Journal of Neurology, 8 (suppl 5): 59-74, 2001.
51. DAMIANO, D. L., QUINLIVAN, J., OWEN, B. F. et al.: Spasticity versus strength in cerebral palsy: relationships among involuntary resistance, voluntary torque, and motor function. European Journal of Neurology, 8 (suppl 5): 40-49, 2001.
52. KOMAN, L. A., BRASHEAR, A., ROSENFELD, S. et al.: Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics, 108: 1062-1071, 2001.
53. BAKHEIT, A. M., SEVERA, S., COSGROVE, A. et al.: Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Developments in Medicine and Child Neurology, 43: 234-238, 2001.
54. LINDER, M., SCHINDLER, G., MICHAELIS, U. et al.: Medium-term functional benefits in children with cerebral palsy treated withbotulinum toxin type A: 1-year follow-up using gross motor function measure. European Journal of Neurology, 8 (suppl 5): 120-126, 2001.
55. GORMLEY, M. E., GAEBLER-SPIRA, D. and DELGADO, M. R.: Use of botulinum toxin type A in pediatrie patients with cerebral palsy: a three-center retrospective chart review. Journal of Child Neurology, 16: 113-118, 2001.
56. DETREMBLEUR, C., LEJEUNE, T. M., RENDERS, A. et al.: Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy. Movement Disorders, 17: 162169, 2002.
57. DURSUN, N., DURSUN, E. and ALICAN, D.: The role of botulinum toxin A in the management of lower limb spasticity in patients with cerebral palsy. International Journal of Clinical Practice, 56: 564-567, 2002.
58. PARK, E. S., PARK, C. I., KIM, D. Y. et al.: The effect of spasticity on cortical somatosensory-evoked potentials: changes of cortical somatosensory-evoked potentials after botulinum toxin type A injection. Archives in Physical Medicine Rehabilitation, 83: 15921596, 2002.
59. BAKER, R., JASINSKI, M., MACIAG-TYMECKA, I. et al.: Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Developments in Medicine and Child Neurology, 44: 666-675, 2002.
60. BANG, M. S., CHUNG, S. G., KIM, S. B. et al.: Change of dynamic gastrocnemius and soleus muscle length after block of spastic calf muscle in cerebral palsy. American Journal of Physical Medicine Rehabilitation, 81: 760-764, 2002.
61. HEINEN, F., LINDER, M., MALL, V. et al.: Adductor spasticity in children with cerebral palsy and treatment with botulinum toxin type A--the parents' view of functional outcome. European Journal of Neurology, 6 (suppl 4): S47-S50, 1999.
62. MALL, V., MEINEN, F., KIRSCHNER, J. et al.: Botulinum toxin A in children with adductor spasm: evaluation of therapy using gross motor function measure. Journal of Child Neurology, 15: 214-217, 2000.
63. WILLENBORG, M. J., SHILT, J. S., SMITH, B. P. et al.: Technique for iliopsoas ultrasound-guided active electromyography-directed botulinum A toxin injection in cerebral palsy. Journal of Pediatrie Orthopaedics, 22: 165-168, 2002.
64. KETELAAR, M., VERMEER, A. and HELDERS, P.: Functional motor abilities of children with cerebral palsy: a systematic literature review of assessment measures. Clinical Rehabilitation, 12: 369380, 1998.
65. BARWOOD, S., BAILLIEU, C., BOYD, R. et al.: Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Developments in Medicine and Child Neurology, 42: 116121, 2000.
66. FATTAL-VALEVSKI, A., GILADI, N., DOMANIEVITZ, D. et al.: Parameters for predicting favorable responses to botulinum toxin in children with cerebral palsy. Journal of Child Neurology, 17: 272-277, 2002.
67. CORRY, I. S., COSGROVE, A. P., WALSH, E. G. et al.: Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Developments in Medicine and Child Neurology, 39: 185-193,1997.
68. FEHLINGS, D., RANG, M., GLAZIER, J. et al.: An evaluation of botulinum A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. Journal of Pediatrics, 137: 331-337, 2000
69. FEHLINGS, D., RANG, M., GLAZIER, J. et al.: Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome. European Journal of Neurology, 8 (suppl 5): 145-149, 2001.
70. AUTTI-RAMO, I., LARSEN, A., TAIMO, A. et al.: Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. European Journal of Neurology, 8 (suppl 5): 136144, 2001.
71. AUTTI-RAMO, I., LARSEN, A., PELTONEN, J. et al.: Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia. Newopediatrics, 31: 4-8, 2000.
72. WONG, V., No, A. and SIT, P.: Open-label study of botulinum toxin for upper limb spasticity in cerebral palsy. Journal of Child Neurology, 17: 138-142, 2002.
73. BOYD, R. N., MORRIS, M. E. and GRAHAM, H. K.: Management of upper limb dysfunction in children with cerebral palsy: a systematic review. European Journal of Neurology, 8 (suppl 5): 150166, 2001.
74. JONGERIUS, P. H., ROTTEVEEL, J. J., VANDEN HOOGEN, F. et al.: Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. European Journal of Pediatrics, 160: 509-512, 2001.
75. BOTHWELL, J. E., CLARKE, K., DOOLEY, J. M. et al.: Botulinum toxin A as a treatment for excessive drooling in children. Pediatrie Neurology, 27: 18-22, 2002.
76. SUSKIND, D. L. and TILTON, A.: Clinical study of Botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy. The Larynscope, 112: 73-81, 2002.
77. JONGERIUS, P. H., JOOSTEN, F., HOOGEN, F. J. A. et al.: The treatment of drooling by ultrasound-guided intraglandular injections of Botulinum toxin type A into the salivary glands. The Laryngoscope, 113: 107-111, 2003.